Published in J Am Acad Dermatol on January 01, 2010
Coexistence of psoriasis with bullous pemphigoid. Indian Dermatol Online J (2012) 0.81
Metronidazole-Induced Bullous Pemphigoid: A Case Report. J Clin Diagn Res (2015) 0.75
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol (2005) 4.04
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol (2007) 3.58
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol (2010) 2.67
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 2.41
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol (2004) 2.33
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects. JAMA Dermatol (2013) 1.98
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol (2002) 1.96
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol (2003) 1.94
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol (2011) 1.85
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol (2003) 1.74
Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet (2008) 1.73
Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol (2005) 1.70
Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol (2009) 1.66
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol (2003) 1.53
Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A (2014) 1.48
Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol (2006) 1.46
Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. J Invest Dermatol (2005) 1.44
Back and face involvement in hidradenitis suppurativa. Dermatology (2010) 1.41
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J (2002) 1.35
SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol (2008) 1.33
Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis (2012) 1.32
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol (2002) 1.32
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol (2009) 1.26
Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol (2010) 1.22
SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol (2006) 1.21
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol (2011) 1.20
Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol (2005) 1.18
Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16
Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst (2011) 1.16
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med (2013) 1.15
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol (2013) 1.12
French people and skin diseases: results of a survey using a representative sample. Arch Dermatol (2003) 1.11
Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine (Baltimore) (2015) 1.11
Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol (2004) 1.09
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol (2006) 1.08
Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol (2011) 1.07
Drug-induced skin, nail and hair disorders. Drug Saf (2007) 1.07
Living with acne. A study of adolescents' personal experiences. Dermatology (2007) 1.07
Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol (2011) 1.06
Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol (2006) 1.04
Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol (2006) 1.04
Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol Med (2010) 1.03
Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets. J Biomed Biotechnol (2011) 1.02
Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs (2005) 1.02
Pemphigus in elderly adults: clinical presentation, treatment, and prognosis. J Am Geriatr Soc (2012) 1.00
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol (2014) 0.99
Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol (2002) 0.99
IL4I1: an inhibitor of the CD8⁺ antitumor T-cell response in vivo. Eur J Immunol (2011) 0.98
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Cornea (2009) 0.98
Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One (2012) 0.98
Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol (2011) 0.97
Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis (2007) 0.96
CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol (2004) 0.95
Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol (2003) 0.95
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. Eur J Cancer (2012) 0.95
Impact of STROBE statement publication on quality of observational study reporting: interrupted time series versus before-after analysis. PLoS One (2013) 0.95
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood (2004) 0.93
Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf (2004) 0.93
A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol (2010) 0.93
Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res (2007) 0.93
Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients. J Invest Dermatol (2010) 0.91
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood (2012) 0.91
Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis (2011) 0.91
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol (2013) 0.89
Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol (2006) 0.88
TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS One (2012) 0.87
Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol (2010) 0.86
CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. Exp Dermatol (2012) 0.86
Neutrophilic skin lesions in autoimmune connective tissue diseases: nine cases and a literature review. Medicine (Baltimore) (2014) 0.86
The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis. Clin Cancer Res (2013) 0.86
Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol (2002) 0.86